瑞典系统性红斑狼疮治疗中糖皮质激素与羟氯喹的时间趋势
基于瑞典人口登记链接的新诊断系统性红斑狼疮队列(n=3891,女性83%,平均年龄48.8岁,2005-2021年诊断),通过配药记录分析诊断后5年内糖皮质激素与羟氯喹治疗模式随时间的变化。诊断后第一年糖皮质激素治疗比例为68.3%;第五年该比例从54.1%降至46.3%。5年累积糖皮质激素剂量中位减少753 mg(90% CI:减少1560 mg至增加106 mg),羟氯喹5年覆盖天数比例中位增加28.6%(90% CI:21.9%至36.2%)。
要点
- 诊断后第一年糖皮质激素治疗比例为68.3%,第五年该比例从54.1%降至46.3%。
- 5年累积糖皮质激素剂量中位减少753 mg(90% CI:减少1560 mg至增加106 mg)。
- 羟氯喹5年覆盖天数比例中位增加28.6%(90% CI:21.9%至36.2%)。
核心结论
- 糖皮质激素暴露的适度减少和羟氯喹覆盖的显著增加与系统性红斑狼疮管理建议的变化一致。
- 治疗优化和持续提高认识对于确保平等护理和改善临床结局仍然至关重要。
研究设计与样本
- 通过瑞典人口登记链接识别2005年至2021年间新诊断系统性红斑狼疮的患者队列(n=3891,女性83%,平均年龄48.8岁),获取配药、住院、专科门诊和患者特征信息。
- 使用可视化、逻辑回归和分位数回归分析治疗模式(包括糖皮质激素和羟氯喹的累积暴露及治疗组合)与诊断年份和患者特征的关系。
主要发现
- 诊断后第一年内接受糖皮质激素治疗的系统性红斑狼疮患者比例在整个研究期间为68.3%。
- 第五年接受糖皮质激素治疗的比例从54.1%降至46.3%。
- 归因于日历年的5年累积糖皮质激素剂量中位减少753 mg(90% CI:减少1560 mg至增加106 mg),最高暴露水平患者减少的趋势更为明显。
- 5年羟氯喹覆盖天数比例中位增加28.6%(90% CI:21.9%至36.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: It is unknown to what extent updated treatment recommendations regarding glucocorticoids (GC) and hydroxychloroquine (HCQ) for patients with systemic lupus erythematosus (SLE) have been incorporated into clinical practice. Based on filled dispensations we examined treatment patterns the first 5 years after SLE diagnosis in Sweden, trends over time and relationship to patient characteristics. METHODS: A cohort of patients with newly diagnosed SLE between 2005 and 2021 with information on drug dispensations, hospitalizations, specialized outpatient visits and patient characteristics were identified through a linkage of Swedish population registers (n = 3891, 83% females, mean age 48.8). Treatment patterns, including accumulated exposure to GC and HCQ and combinations of treatments, were investigated in relation to year of diagnosis and patient characteristics using visualizations, logistic regression and quantile regression analysis. RESULTS: The proportion of SLE patients treated with GC during the first year after diagnosis was 68.3% over the study period. For the fifth year it decreased from 54.1% to 46.3%. The median decrease in 5-year cumulative GC dose attributable to calendar year was 753 mg (90% CI: 1560 mg decrease, 106 mg increase) with a more pronounced trend towards fewer patients on the highest exposure levels. The median increase in proportion of days covered with HCQ during 5 years was 28.6% (90% CI: 21.9%, 36.2%). CONCLUSION: The modest reduction of GC exposure and substantial increase in HCQ coverage over time aligns with changes in recommendations for SLE management. However, treatment optimization and continued efforts to raise awareness remain essential to ensure equal care and improve clinical outcomes.
引用
- Dominicus A, Mageau A, Nguyen NV, et al. Temporal trends in glucocorticoids and hydroxychloroquine for treatment of systemic lupus erythematosus in Sweden. Rheumatology (Oxford). 2025. PMID: 40209080. doi:10.1093/rheumatology/keaf192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。